HVHaris S. Vasiliadis

Haris S. Vasiliadis

*This is an algorithmically generated author record based on publicly available information.

Haris S. Vasiliadis has a total of 301 co-authors. Here are the top co-authors by number of shared publications:

  • Georgia Salanti

    Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

    4 shared publications
  • Ian Shrier

    Jewish General Hospital, Lady Davis Institute, McGill University; Centre for Clinical Epidemiology; 3755 Cote Ste-Catherine Road Montreal QC Canada H3T 1E2

    4 shared publications
  • Rob Jpm Scholten

    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University; Cochrane Netherlands; Room Str. 6.126 P.O. Box 85500 Utrecht Netherlands 3508 GA

    3 shared publications
  • Anna Batistatou

    2 shared publications
  • Georgia Salanti

    University of Bern; Institute of Social and Preventive Medicine (ISPM); Finkenhubelweg 11 Bern Switzerland 3005

    2 shared publications
  • Jason Wasiak

    The Epworth Hospital; Department of Radiation Oncology; 89 Bridge Rd Richmond Australia 3121

    2 shared publications

Latest Publications

  • Open release for carpal tunnel syndrome

    by Haris S Vasiliadis, Maria Eleni Sakellaridou, Ian Shrier, Georgia Salanti, Rob Jpm Scholten


  • Open Access

    Glucosamine and chondroitin for the treatment of osteoarthritis

    by Haris S Vasiliadis, Konstantinos Tsikopoulos

    Glucosamine and chondroitin for the treatment of osteoarthritis


  • Knee Cartilage Repair

    by Lars G. Peterson, Haris S. Vasiliadis

  • Open release for carpal tunnel syndrome

    by Haris S Vasiliadis, Maria Eleni Sakellaridou, Ian Shrier, Georgia Salanti, Rob Jpm Scholten


  • Endoscopic release for carpal tunnel syndrome

    by Haris S Vasiliadis, Petros Georgoulas, Ian Shrier, Georgia Salanti, Rob J P M Scholten

    Background Carpal tunnel syndrome (CTS) is the most common compressive neuropathy of the upper extremity. It is caused by increased pressure on the median nerve between the transverse carpal ligament and the carpal bones. Surgical treatment consists of the release of the nerve by cutting the transverse carpal ligament. This can be done either with an open approach or endoscopically. Objectives To assess the effectiveness and safety of the endoscopic techniques of carpal tunnel release compared to any other surgical intervention for the treatment of CTS. More specifically, to evaluate the relative impact of endoscopic techniques in relieving symptoms, producing functional recovery (return to work and return to daily activities) and reducing complication rates. Search methods This review fully incorporates the results of searches conducted up to 5 November 2012, when we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE. There were no language restrictions. We reviewed the reference lists of relevant articles and contacted trial authors. We also searched trial registers for ongoing trials. We performed a preliminary screen of searches to November 2013 to identify any additional recent publications. Selection criteria We included any randomised controlled trials (RCTs) and quasi‐RCTs comparing endoscopic carpal tunnel release (ECTR) with any other surgical intervention for the treatment of CTS. Data collection and analysis We used standard methodological procedures expected by the Cochrane Collaboration. Main results Twenty‐eight studies (2586 hands) were included. Twenty‐three studies compared ECTR to standard open carpal tunnel release (OCTR), five studies compared ECTR with OCTR using a modified incision, and two studies used a three‐arm design to compare ECTR, standard OCTR and modified OCTR. At short‐term follow‐up (three months or less), only one study provided data for overall improvement. We found no differences on the Symptom Severity Scale (SSS) (scale zero to five) (five studies, standardised mean difference (SMD) ‐0.13, 95% CI ‐0.47 to 0.21) or on the Functional Status Scale (FSS) (scale zero to five) (five studies, SMD ‐0.23, 95% CI ‐0.60 to 0.14) within three months postoperatively between ECTR and OCTR. Pain scores favoured ECTR over conventional OCTR (two studies, SMD ‐0.41, 95% CI ‐0.65 to ‐0.18). No difference was found between ECTR and OCTR (standard and modified) when pain was assessed on non‐continuous dichotomous scales (five studies, RR 0.69, 95% CI 0.33 to 1.45). Also, no difference was found in numbness (five studies, RR 1.14; 95% CI 0.76 to 1.71). Grip strength was increased after ECTR when compared with OCTR (six studies, SMD 0.36, 95% CI 0.09 to 0.63). This corresponds to a mean difference (MD) of 4 kg (95% CI 1 to 6.9 kg) when compared with OCTR, which is probably not clinically significant. In the long term (more than three months postoperatively) there was no significant difference in overall improvement between ECTR and OCTR (four studies, RR 1.04, 95% CI 0.95 to 1.14). SSS and FSS were also similar in both treatment groups (two studies, MD 0.02, 95% CI ‐0.18 to 0.22 for SSS and MD 0.01, 95% CI ‐0.14 to 0.16 for FSS). ECTR and OCTR did not differ in the long term in pain (six studies, RR 0.88, 95% CI 0.57 to 1.38) or in numbness (four studies, RR 0.64, 95% CI 0.31 to 1.35). Results from grip strength testing favoured ECTR (two studies, SMD 1.13, 95% CI 0.56 to 1.71), corresponding to an MD of 11 kg (95% CI 6.2 to 18.81). Participants treated with ECTR returned to work or daily activities eight days earlier than participants treated with OCTR (four studies, MD ‐8.10 days, 95% CI ‐14.28 to ‐1.92 days). Both treatments were equally safe with only a few reports of major complications (mainly with complex regional pain syndrome) (15 studies, RR 1.00, 95% CI 0.38 to 2.64). ECTR resulted in a significantly lower rate of minor complications (18 studies, RR 0.55, 95% CI 0.38 to 0.81), corresponding to a 45% relative drop in the probability of complications (95% CI 62% to 19%). ECTR more frequently resulted in transient nerve problems (ie, neurapraxia, numbness, and paraesthesiae), while OCTR had more wound problems (ie, infection, hypertrophic scarring, and scar tenderness). ECTR was safer than OCTR when the total number of complications were assessed (20 studies, RR 0.60, 95% CI 0.40 to 90) representing a relative drop in the probability by 40% (95% CI 60% to 10%). Rates of recurrence of symptoms and the need for repeated surgery were comparable between ECTR and OCTR groups. The overall risk of bias in studies that contribute data to these results is rather high; fewer than 25% of the included studies had adequate allocation concealment, generation of allocation sequence or blinding of the outcome assessor. The quality of evidence in this review may be considered as generally low. Five of the studies were presented only as abstracts, with insufficient information to judge their risk of bias. In selection bias, attrition bias or other bias (baseline differences and financial conflict of interest) we could not reach a safe judgement regarding a high or low risk of bias. Blinding of participants is impossible due to the nature of interventions. We identified three further potentially eligible studies upon updating searches just prior to publication. These compared ECTR with OCTR (two studies) or mini‐open carpal tunnel release (one study) and will be fully assessed when we update the review. Authors' conclusions In this review, with support from low quality evidence only, OCTR and ECTR for carpal tunnel release are about as effective as each other in relieving symptoms and improving functional status, although there may be a functionally significant benefit of ECTR over OCTR in improvement in grip...


  • Open Access

    Low-grade central osteosarcoma of distal femur, resembling fibrous dysplasia

    by Haris S Vasiliadis, Christina Arnaoutoglou, Sotiris Plakoutsis, Michalis Doukas, Anna Batistatou, Theodoros A Xenakis

    We report a case of a 32 year-old male, admitted for a lytic lesion of the distal femur. One month after the first X-ray, clinical and imaging deterioration was evident. Open biopsy revealed fibrous dysplasia. Three months later, the lytic lesion had spread to the whole distal third of the femur reaching the articular cartilage. The malignant clinical and imaging features necessitated excision of the lesion and reconstruction with a custom-made total knee arthroplasty. Intra-operatively, no obvious soft tissue infiltration was evident. Nevertheless, an excision of the distal 15.5 cm of the femur including 3.0 cm of the surrounding muscles was finally performed. The histological examination of the excised specimen revealed central low-grade osteosarcoma. Based on the morphological features of the excised tumor, allied to the clinical findings, the diagnosis of low-grade central osteosarcoma was finally made although characters of a fibrous dysplasia were apparent. Central low-grade osteosarcoma is a rare, well-differentiated sub-type of osteosarcoma, with clinical, imaging, and histological features similar to benign tumours. Thus, initial misdiagnosis is usual with the condition commonly mistaken for fibrous dysplasia. Central low-grade osteosarcoma is usually treated with surgery alone, with rare cases of distal metastases. However, regional recurrence is quite frequent after close margin excision.


  • Contributors

    by Aryeh M. Abeles, Paolo Aglietti, Azhar A. Ali, Annunziato Amendola, Allen F. Anderson, Christian Noel Anderson, Jason D. Archibald, Elizabeth Arendt, Jean-Noël Argenson, Amy F. Austin, et al.

  • Open Access

    El papel de las revisiones sistemáticas. Comentarios

    by Haris S. Vasiliadis, Arturo Martí-Carvajal, Georgia Salanti

  • Autologous chondrocyte implantation for full thickness articular cartilage defects of the knee

    by Haris S Vasiliadis, Jason Wasiak

    Treatments for managing articular cartilage defects of the knee, including drilling and abrasion arthroplasty, are not always effective. When they are, long-term benefits may not be maintained and osteoarthritis may develop. An alternative is autologous chondrocyte implantation (ACI), the surgical implantation of healthy cartilage cells into the damaged areas. To determine the efficacy and safety of ACI in people with full thickness articular cartilage defects of the knee. We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (3 December 2008), the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 4), MEDLINE (1950 to November Week 3 2008), EMBASE (1980 to Week 48 2008), SPORTDiscus (3 December 2008), the WHO International Clinical Trials Registry Platform (4 December 2008), and Current Controlled Trials (3 December 2008). Randomised and quasi-randomised trials comparing ACI with any other type of treatment (including no treatment or placebo) for symptomatic cartilage defects of the medial or lateral femoral condyle, femoral trochlea or patella. Review authors selected studies for inclusion independently. We assessed risk of bias based on adequacy of the randomisation and allocation concealment process, potential for selection bias after allocation and level of masking. We did not pool data due to clinical and methodological heterogeneity. Six heterogeneous trials were identified with 431 participants. Methodological flaws of the included trials included incomplete follow-up and inadequate reporting of outcomes. Three trials compared ACI versus mosaicplasty. One reported statistically significant results in favour of ACI at one year in the numbers of people with 'good' or 'excellent' functional results. Conversely, another trial found significant improvement for the mosaicplasty group when assessed using one functional scoring system at two years, but no statistically significant differences based on two other scoring systems. A third trial found no difference between ACI and mosaicplasty, 10 months on average after the surgery.There was no statistically significant difference in functional outcomes at two years in single trials comparing ACI with microfracture or characterised chondrocyte implantation versus microfracture. The results of the sixth trial comparing matrix-guided ACI versus microfracture were undermined by the severe loss to follow-up. There is insufficient evidence to draw conclusions on the use of ACI for treating full thickness articular cartilage defects in the knee. Further good quality randomised controlled trials with long-term functional outcomes are required.


  • Autologous chondrocyte implantation for the treatment of cartilage lesions of the knee: a systematic review of randomized studies

    by Haris S. Vasiliadis, Jason Wasiak, Georgia Salanti

    Autologous chondrocyte implantation (ACI) techniques are becoming more popular for the treatment of full thickness cartilage lesions of the knee joint. However, there is no systematic information for the efficacy of the new generation ACI techniques compared to other treatment options. A systematic review of the existing evidence from randomized clinical trials of ACI treatment would contribute to understanding the advantages and limitations of this method and would inform the planning of future studies. Using pre‐defined criteria, we searched a number of electronic databases to identify all the existing randomized control trials of any type of ACI treatment. Risk of bias was assessed and an analysis of the reported outcomes was performed. Information on the clinical efficacy and safety of ACI compared to other interventions was collected and presented. Nine trials were identified with 626 patients. Patients ranged from 15 to 52 years, and the size of treated lesions was between 1 and 22 cm2. ACI was associated with improvement in clinical outcomes compared to baseline. However, the body of evidence did not suggest any superiority of ACI over other treatments. Complication rates were comparable between interventions except from an increased rate of graft hypertrophies after ACI with periosteum. ACI is an effective treatment for full thickness chondral defects of the knee, providing an improvement of clinical outcomes. However, there is insufficient data to say whether ACI is superior to other treatment strategies. More high quality studies and harmonization in the reported outcomes are needed before specific suggestions for practice can be made.